Abstract
BackgroundImmunotherapy is an effective therapeutic approach for multiple human cancer types. However, the correlations between EVA1C and patients’ prognosis as well as immune infiltration remain obscure. Herein, we employed transcriptomic and clinical data extracted from two independent databases to systematically investigate the role of EVA1C in the oncological context.MethodsThe differential expression of EVA1C was analyzed via TCGA and Oncomine databases. We evaluated the influence of EVA1C on clinical prognosis using Kaplan-Meier plotter. We then used the expression profiler to calculate stromal score, immune score, and ESTIMATE score based on the ESTIMATE algorithm. The abundance of infiltrating immune cells was calculated via TIMER. The correlations between EVA1C expression and immune infiltration levels were analyzed in two independent cohorts.ResultsIn patients with World Health Organization (WHO) grade II/III glioma, high EVA1C expression was associated with malignant clinicopathological features and poor overall survival in both cohorts. EVA1C expression was positively associated with immune infiltration levels of B cell, CD4+ T cell, neutrophil, macrophage, and dendritic cells (DCs). Besides, EVA1C expression strongly correlated with diverse immune marker sets. And the predictive power of EVA1C was better than that of other indicators in predicting high immune infiltration levels in glioma.ConclusionsFor the first time, we identified the overexpression of EVA1C in glioma, which was tightly correlated with the high infiltration levels of multiple immune cells as well as poor prognosis. Meanwhile, EVA1C might be a potential biomarker for predicting high immune infiltration in WHO grade II/III gliomas.
Highlights
Human brain is derived from the neural ectoderm and accounts for about half of all intracranial tumor incidences [1]
We compared the differences in EVA1C expression between glioma and normal brain tissues by GEPIA website, and found that the mRNA levels of EVA1C were upregulated in glioblastoma (GBM) (Figure 1A)
Immuno histochemistry results showed that EVA1C protein was strongly over-expressed in GBM compared with normal brain tissues (Figure 1B)
Summary
Human brain is derived from the neural ectoderm and accounts for about half of all intracranial tumor incidences [1]. Diffuse WHOII/III glioma is a lethal threat to young adults, which tends to have a wide range of genetic and transcriptional heterogeneity [3]. Compared with WHOIV gliomas, the course of WHOII/III gliomas is very slow. In the vast majority of WHOII/III gliomas, IDH mutation is present in 84% of cases, and 1p/19q codeletion is present in 35% of cases. IDH mutation tends to occur in the early stage of gliomas [3]. Adjuvant therapeutics have improved the prognosis of glioma to some extent, the overall survival (OS) of glioma patients remains poor [5, 6]. The correlations between EVA1C and patients’ prognosis as well as immune infiltration remain obscure. We employed transcriptomic and clinical data extracted from two independent databases to systematically investigate the role of EVA1C in the oncological context
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
